A cure for sickle cell disease will require that functional globin genes be transferred to a large percentage of hematopoietic stem cells. Because the majority of stem cells are normally not dividing, but undergo extensive proliferation during differentiation, this will require the stable integration of transferred genes into non-dividing cells. Retroviral vectors based on murine leukemia virus (MLV) are only able to transduce a small percentage of hematopoietic stem cells in large animal models. One reason for these disappointing results is that efficient transduction by MLV vectors requires cell division. Adeno-associated virus (AAV) vectors represent an alternative to MLV vectors, but our recent results show that efficient transduction by AAV vectors also requires cell proliferation. The objective of this project is to develop alternative vectors and techniques for the transduction of non-dividing cells. Retroviral vectors will be constructed based on visna virus and human foamy virus (HFV). Visna virus is a lentivirus capable of replicating in non-dividing cells, and preliminary experiments suggest that HFV vectors transduce non- dividing cells. The ability of these vectors to transduce and integrate in non-dividing cells will be tested using stationary fibroblast cultures. The transduction of hematopoietic stem cells will be tested using cultured human CD34+ cells and gene transfer experiments in mice, dogs and baboons. New techniques will also be developed for AAV vectors that increase the transduction of non-dividing cells by inducing DNA repair, and applied to the same experimental systems. Globin gene expression will be measured from visna, HFV and AAV vectors containing globin constructs and compared to MLV vectors, in order to determine the optimal vector system for sickle cell gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL053750-05
Application #
6110421
Study Section
Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Constantinou, Varnavas C; Bouinta, Asimina; Karponi, Garyfalia et al. (2017) Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with ?-thalassemia major. Transfusion 57:1031-1039
Gori, Jennifer L; Butler, Jason M; Kunar, Balvir et al. (2017) Endothelial Cells Promote Expansion of Long-Term Engrafting Marrow Hematopoietic Stem and Progenitor Cells in Primates. Stem Cells Transl Med 6:864-876
Psatha, Nikoletta; Karponi, Garyfalia; Yannaki, Evangelia (2016) Optimizing autologous cell grafts to improve stem cell gene therapy. Exp Hematol 44:528-39
Li, Li B; Ma, Chao; Awong, Geneve et al. (2016) Silent IL2RG Gene Editing in Human Pluripotent Stem Cells. Mol Ther 24:582-91
Karponi, Garyfalia; Psatha, Nikoletta; Lederer, Carsten Werner et al. (2015) Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood 126:616-9
Vierstra, Jeff; Reik, Andreas; Chang, Kai-Hsin et al. (2015) Functional footprinting of regulatory DNA. Nat Methods 12:927-30
Qi, Heyuan; Liu, Mingdong; Emery, David W et al. (2015) Functional validation of a constitutive autonomous silencer element. PLoS One 10:e0124588
Liu, Mingdong; Maurano, Matthew T; Wang, Hao et al. (2015) Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol 33:198-203
Polak, Paz; Karli?, Rosa; Koren, Amnon et al. (2015) Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518:360-364
Chandrasekaran, Devikha; Nakamoto, Betty; Watts, Korashon L et al. (2014) Modeling promising nonmyeloablative conditioning regimens in nonhuman primates. Hum Gene Ther 25:1013-22

Showing the most recent 10 out of 161 publications